Effectiveness of 23-valent pneumococcal polysaccharide vaccine in adults aged 60 years and over in the Region of Madrid, Spain, 2008-2011
Autor: | M Ordobás Gavín, Luis García-Comas, J A Taveira Jimenez, F Martin Martinez, M. A. Gutiérrez Rodríguez, M D Lasheras Carbajo, J.C. Sanz Moreno, E Cordoba Deorador, D Iniesta Fornies, A Arce Arnáez |
---|---|
Rok vydání: | 2014 |
Předmět: |
Serotype
Male Risk Pediatrics medicine.medical_specialty Epidemiology Notifiable disease Pneumococcal Infections Pneumococcal Vaccines Virology Screening method medicine Humans In patient Sex Distribution Aged Aged 80 and over Vaccines Conjugate business.industry Incidence (epidemiology) Incidence Vaccination Public Health Environmental and Occupational Health Middle Aged Pneumococcal polysaccharide vaccine Streptococcus pneumoniae Treatment Outcome Spain Population Surveillance Cohort Female Seasons business |
Zdroj: | Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 19(40) |
ISSN: | 1560-7917 |
Popis: | Invasive pneumococcal disease (IPD) is a notifiable disease in the Region of Madrid. The 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended for children and adults aged two years or over with a high risk of disease, and for all adults aged 60 and over. We describe the evolution of IPD incidence from 2008 to 2011 in people aged 60 years and over and PPV23 vaccine effectiveness (VE). VE is estimated using both the screening method and indirect cohort method. The incidence of IPD varied from 20.0 in 2008 to 15.2 per 100,000 inhabitants in 2011 (RR: 0.8; 95% CI: 0.6–0.9). Adjusted VE estimated with the screening method was 68.2% (95% CI: 56.2–76.9). VE with the Broome method was 44.5% (95% CI: 23.8–59.6) for all PPV23 serotypes, and 64.4% (95% CI: 45.2–76.8) for PPV23 serotypes not included in conjugate vaccines. VE was lower in patients aged 80 years and older (25.5%; 95% CI:-23.2 to 55.0) and those with highrisk medical conditions (31.7%; 95% CI: -2.2 to -54.4). Adjusted VE was 44.5% (95% CI: 19.4-61.8) within 5 years of vaccination and 32.5% (95% CI: -5.6 to 56.9) after 5 years. These results are compatible with current recommendations for PPV23. |
Databáze: | OpenAIRE |
Externí odkaz: |